Bolt Biotherapeutics Q2 revenue falls to $5,000; net loss narrows to $7.7 million
Bolt Biotherapeutics reported second-quarter 2026 collaboration revenue of $5,000, down from $1.8 million a year earlier, while its net loss narrowed to $7.7 million from $8.6 million on lower research and general and administrative expenses. Cash, cash equivalents and marketable securities were $18.1 million at June 30, 2026, which the company expects to fund operations into the first quarter of 2027, and it said initial clinical data for its lead candidate BDC-4182 is expected with third-quarter 2026 results.
Key points
- Collaboration revenue was $5,000 for Q2 2026, versus $1.8 million in Q2 2025
- Net loss was $7.7 million, or $4.57 per share, versus $8.6 million, or $4.46 per share, a year earlier
- Cash and marketable securities of $18.1 million as of June 30, 2026, expected to fund operations into 1Q 2027
- Initial BDC-4182 clinical data expected with 3Q 2026 results; the rest of the pipeline is on hold
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.